Document
IPR2018-00892, No. 1023 Exhibit - Ex 1023 Tong (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1023 Exhibit - Ex 1023 Tong (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1026 Exhibit - Ex 1026 Gong (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1026 Exhibit - Ex 1026 Gong (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1005 Exhibit - Ex 1005 Pinto (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1005 Exhibit - Ex 1005 Pinto (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1003 Exhibit - Ex 1003 File history of 945 patent (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1003 Exhibit - Ex 1003 File history of 945 patent (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
IPR2018-00892, No. 2011 Exhibit - US Patent Application Publication No 20120087978 to Richard G Nause published Apr 12, 2012 (P.T.A.B. Jul. 18, 2018)
Cite Document
IPR2018-00892, No. 2011 Exhibit - US Patent Application Publication No 20120087978 to Richard G Nause published Apr 12, 2012 (P.T.A.B. Jul. 18, 2018)
+ More Snippets
Document
IPR2018-00892, No. 1007 Exhibit - Ex 1007 US Patent No 6,967,208 (P.T.A.B. Apr. 5, 2018)
Cite Document
IPR2018-00892, No. 1007 Exhibit - Ex 1007 US Patent No 6,967,208 (P.T.A.B. Apr. 5, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962LP1 (U.S. Pat. App. Jun. 19, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962LP1 (U.S. Pat. App. Jun. 19, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962KP1 (U.S. Pat. App. Jun. 15, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962KP1 (U.S. Pat. App. Jun. 15, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979626P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979626P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962AP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962AP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979620P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979620P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979624P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979624P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797961ZP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797961ZP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979621P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979621P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962FP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962FP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets